| Read Time: < 1 minute | news

Study Revealed Permanent Hair Loss

May 2012 – A study published in the Annals of Oncology revealed that, of the 20 female participants who received Taxotere, 19 developed permanent hair loss. One participant who was being treated for recurrent breast cancer had previously undergone chemotherapy with a different drug and had complete hair regrowth, but after using Taxotere, she suffered from permanent hair loss. Reference: “Taxotere Lawsuit – Permanent Hair Loss and Illegal Marketing.” Drugwatch.com, 20 Apr. 2020, www.drugwatch.com/taxotere/lawsuits/

Continue Reading

| Read Time: < 1 minute | news

Zostavax Changes Label to Treat Individuals Aged 50-59

March 2011 — A label change was required by the FDA to include data supporting use for individuals from the ages of 50-59. Reference: Center for Biologics Evaluation and Research. “Approved Products – Zostavax.” Internet Archive Wayback Machine, Center for Biologics Evaluation and Research, wayback.archive-it.org/7993/20170722150959/https:/www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136941.htm.

Continue Reading

| Read Time: < 1 minute | news

Zostavax Leads to Retinal Necrosis

2011 — A study published in JAMA Ophthalmology reveals that Zostavax vaccine likely leads to retinal necrosis. References: Center for Biologics Evaluation and Research. “Approved Products – Zostavax.” Internet Archive Wayback Machine, Center for Biologics Evaluation and Research, wayback.archive-it.org/7993/20170722150959/https:/www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136941.htm. Charkoudian, Leon D. “Acute Retinal Necrosis After Herpes Zoster Vaccination.” Archives of Ophthalmology, JAMA Network, 1 Nov. 2011, jamanetwork.com/journals/jamaophthalmology/fullarticle/1106674.

Continue Reading

| Read Time: < 1 minute | news

Study Revealed Percentage of Patients Suffered Long-Term Hair Loss

December 2010 – A release of documents from the Sanofi-funded GEICAM 9805 study revealed that around 9.2% of patients suffered hair loss that lasted more than a decade. Reference: “Taxotere Lawsuit – Permanent Hair Loss and Illegal Marketing.” Drugwatch.com, 20 Apr. 2020, www.drugwatch.com/taxotere/lawsuits/

Continue Reading

| Read Time: < 1 minute | news

Woman Experiences Worse Keratitis After Zostavax

2010 — A 50-year-old woman endured the worsening of her keratitis after being vaccinated with Zostavax. References: Zostavax.” Internet Archive Wayback Machine, Center for Biologics Evaluation and Research, wayback.archive-it.org/7993/20170722150959/https:/www.fda.gov/BiologicsBloodvaccines/Vaccines/ApprovedProducts/ucm136941.htm. Khalifa, Yousuf M. “Exacerbation of Zoster Interstitial Keratitis After Zoster Vaccination in an Adult.” Archives of Ophthalmology, JAMA Network, 1 Aug. 2010, www.jamanetwork.com/journals/jamaophthalmology/fullarticle/426103.

Continue Reading

| Read Time: < 1 minute | Defective Consumer Devices

Glyphosate Exposure Shown To Double Chance Of Cancer

2008 — Researchers concluded that glyphosate exposure doubled a person’s chances of developing non-Hodgkin’s lymphoma in 2008 following a study of Swedish citizens who were exposed to a number of pesticides. Reference:  Moncivais, Katy. “Roundup Cancer Lawsuit: 2020 Updates & Settlements.” Consumer Safety, 8 Jan. 2021, www.consumersafety.org/product-lawsuits/roundup/

Continue Reading

| Read Time: < 1 minute | Defective Consumer Devices

Roundup’s Popularity Grows

2007 — Roundup became the most used herbicide in the U.S. by 2007.  The result of Roundup’s rising popularity was Roundup Ready crops, which began hitting the market in the late 1990s.  From the introduction of Roundup Ready crops through 2016, the global glyphosate usage increased by more than 15 times.  The U.S. made up 72% of the usage during that time. Reference:  Moncivais, Katy. “Roundup Cancer Lawsuit: 2020 Updates & Settlements.” Consumer Safety, 8 Jan. 2021, www.consumersafety.org/product-lawsuits/roundup/

Continue Reading

| Read Time: < 1 minute | news

FDA Raises Concern about Incretin Mimetics

2007:  The Food and Drug Administration first raised concern about incretin mimetics in 2007.  They warned that incretin mimetics, especially exenatide (Byetta and Byuderon) and sitagliptin (Janumet and Januvia), could cause pancreatic diseases.  The warning followed reports that a rising number of incretin mimetics users were being diagnosed with acute pancreatitis and pancreatic cancer. Reference:  “FDA Investigating Reports of Possible Increased Risk of Pancreatitis..” U.S. Food and Drug Administration, FDA, www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre.

Continue Reading

| Read Time: < 1 minute | news

Study Found Taxotere Caused Permanent Alopecia in 6% of Women

December 2006 – A study conducted by the Rock Mountain Cancer Centers found that Taxotere caused 6% of women to suffer permanent alopecia. Reference: “Taxotere Lawsuit – Permanent Hair Loss and Illegal Marketing.” Drugwatch.com, 20 Apr. 2020, www.drugwatch.com/taxotere/lawsuits/

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved For Yet Another Cancer Treatment

October 2006 — Taxotere was approved for use in combination with cisplatin and fluorouracil for patients being treated for inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). Reference: “TAXOTERE® Receives U.S. FDA Approval for the Treatment of Patients with Head and Neck Cancer.” Sanofi, www.news.sanofi.us/press-releases?item=118381

Continue Reading